De P - Search Results

1

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Sicklick JK, et al. Among authors: de p. Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011206 Free PMC article. Clinical Trial.

2

Whither HER2-related therapeutics?

De P, Leyland-Jones B. De P, et al. J Clin Oncol. 2010 Mar 1;28(7):1091-6. doi: 10.1200/JCO.2009.25.8624. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124168 No abstract available.

3

Human epidermal growth factor receptor 2 testing: where are we?

De P, Smith BR, Leyland-Jones B. De P, et al. J Clin Oncol. 2010 Oct 1;28(28):4289-92. doi: 10.1200/JCO.2010.29.5071. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697080 No abstract available.

4

Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.

De P, Miskimins K, Dey N, Leyland-Jones B. De P, et al. Cancer Treat Rev. 2013 Aug;39(5):403-12. doi: 10.1016/j.ctrv.2012.12.002. Epub 2013 Jan 23. Cancer Treat Rev. 2013. PMID: 23352077 Review.

5

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

De P, Hasmann M, Leyland-Jones B. De P, et al. Cancer Treat Rev. 2013 Dec;39(8):925-34. doi: 10.1016/j.ctrv.2013.02.006. Epub 2013 Apr 3. Cancer Treat Rev. 2013. PMID: 23562214 Review.

6

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.

Sun Y, Dey N, Brammer M, De P, Leyland-Jones B. Sun Y, et al. Among authors: de p. Cancer Chemother Pharmacol. 2013 Oct;72(4):733-45. doi: 10.1007/s00280-013-2233-7. Cancer Chemother Pharmacol. 2013. PMID: 23959459

7

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B. Dey N, et al. Among authors: de p. PLoS One. 2013 Oct 15;8(10):e77425. doi: 10.1371/journal.pone.0077425. eCollection 2013. PLoS One. 2013. PMID: 24143235 Free PMC article.

8

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N. De P, et al. Neoplasia. 2014 Jan;16(1):43-72. doi: 10.1593/neo.131694. Neoplasia. 2014. PMID: 24563619 Free PMC article.

9

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

De P, Carlson J, Leyland-Jones B, Dey N. De P, et al. Oncotarget. 2014 Jul 15;5(13):4581-602. doi: 10.18632/oncotarget.2127. Oncotarget. 2014. PMID: 25015035 Free PMC article. Review.

10

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Dey N, Leyland-Jones B, De P. Dey N, et al. Among authors: de p. Am J Cancer Res. 2014 Dec 15;5(1):1-19. eCollection 2015. Am J Cancer Res. 2014. PMID: 25628917 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

550 results

Search Page